ABHD12

Across TCGA pan-cancer cohorts, ABHD12 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ABHD12’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ABHD12 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ABHD12 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where ABHD12 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ABHD12 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	+0.532	<.001	11	view →
COAD	Female	II,III,IV	+0.322	<.001	10	view →
HNSC	Male	IV	+0.326	<.001	8	view →
PDAC	Male	All	−0.520	<.001	4	view →
LSCC	All	All	+0.107	<.001	3	view →
OV	All	All	+0.333	.026	2	view →
LUAD	Female	III,IV	+0.287	.010	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ABHD12–CCRCC

Open the CCRCC breakdown →